Q32 Bio INC 8-K filings

Homology Medicines and Q32 Bio have finalized their merger, creating a new publicly traded company focused on developing treatments for autoimmune and inflammatory diseases.

Homology Medicines has amended its previous 8-K filing to update the effective date of its 1-for-18 reverse stock split to March 26, 2024, and to announce the approval of its Nasdaq listing application.

Homology Medicines will implement a 1-for-18 reverse stock split effective March 25, 2024, in preparation for its merger with Q32 Bio Inc.

Homology Medicines' stockholders approved the merger with Q32 Bio and several key proposals, including an increase in authorized shares and a reverse stock split, at a special meeting on March 15, 2024.

Homology Medicines has provided supplemental disclosures to its proxy statement/prospectus related to its merger with Q32 Bio, addressing a lawsuit and demand letters from stockholders.

Homology Medicines will acquire Q32 Bio in a reverse triangular merger, creating a combined entity focused on immune therapeutics, with a concurrent private placement to fund operations.